Clinical studies have confirmed the safety of low‐dose IL‐2 in therapying various autoimmune and inflammatory chronic diseases (including RA, ankylosing spondylitis, SLE, and psoriasis).4 This evidence concerns the gene IL2 and ankylosing spondylitis.